This suggests that tofersen may have disease-modifying effects in some SOD1-ALS patients, but definitive therapeutic efficacy remains to be validated in further clinical trials [14, 17, 51]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.